Hodgkin Lymphoma, Adult Clinical Trial
Official title:
Outcome of Hodgkin Lymphoma Patients Over Than 60 Years Treated by Chemotherapy and/or Radiotherapy: a Retrospective Study
Outcome of Hodgkin lymphoma patients over than 60 years treated by chemotherapy and/or radiotherapy: retrospective analysis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04653649 -
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04636255 -
Physical Capacity in Hodgkin Lymphoma Survivors
|
N/A | |
Not yet recruiting |
NCT06421987 -
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
|
||
Recruiting |
NCT05597761 -
Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients
|
||
Completed |
NCT03155425 -
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
|
Phase 2 | |
Recruiting |
NCT03260101 -
Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
|
||
Recruiting |
NCT04776265 -
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
|
||
Recruiting |
NCT04378647 -
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
|
Phase 2 | |
Recruiting |
NCT04758650 -
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
|
Phase 2 | |
Recruiting |
NCT05137886 -
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
|
Phase 2 | |
Recruiting |
NCT05798897 -
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
|
Phase 1 | |
Completed |
NCT04292626 -
Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose
|
Phase 1 | |
Active, not recruiting |
NCT04268706 -
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
|
Phase 2 | |
Recruiting |
NCT04638790 -
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
|
Phase 3 | |
Completed |
NCT01578967 -
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
|
N/A | |
No longer available |
NCT03914885 -
Compassionate Use Re-Infusion of ATLCAR.CD30
|